Anti-CD20 B cell-depleting agents such as rituximab may offer a promising initial disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple ...
Because MS patients who take rituximab have more relapses than those who take ocrelizumab, these two therapies may not be interchangeable in clinical practice. Ocrelizumab was the first licensed ...
An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...
A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...
Discover the latest advancements in multiple sclerosis (MS) treatment, including innovative therapies and strategies for disease prevention and repair. The Multiple Sclerosis International Federation ...
A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...
MedPage Today on MSN
Pregnant or Not, Disability Risk Was Similar for Women With Moderately Severe MS
Overall, women with more advanced MS disability had similar peripartum relapse activity as those with less disability, ...
Between June 1998 and August 2002, 114 patients who had received previous chemotherapy for indolent non-Hodgkin's lymphoma were treated with a standard 4-week course of rituximab. Patients with ...
In patients with AAV, despite treatment with biologics and immunosuppressants, relapse remains a major clinical challenge. In patients with antineutrophil cytoplasmic antibody (ANCA)-associated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback